West Pharmaceutical Services Reports Strong Q2 Performance Driven by HVP Growth
West Pharmaceutical Services, Inc. reported strong second-quarter performance in fiscal year 2026, driven primarily by a 16% organic growth in Proprietary Products and a significant surge of 29% in the Biologics market group. High-Value Product (HVP) Components now account for nearly half of total revenue at 49%, up from 46% last year, as customers increasingly adopt advanced primary containment solutions like FluroTec and NovaPure barrier films. The company's strategic focus on HVP components is being supported by regulatory changes in Europe under Annex 1 standards, which are driving over 800 upgrade projects. Despite a cyber incident in May that impacted the West Vantage segment, operational initiatives helped maintain throughput and capture high-teens growth outside of GLP-1 products. Looking ahead, management raised full-year organic revenue guidance to between 10% and 11%, citing sustained momentum in HVP Components and improved performance from delivery devices. The company also completed the divestiture of its SmartDose business on July 1, which is expected to provide a margin tailwind for the remainder of the year.
Tickers: $WST
Topics: Annex 1 regulations Biologics market earnings HVP Components organic growth